Broad and efficient control of major foodborne pathogenic strains of Escherichia coli by mixtures of plant-produced colicins

Significance Enterohemorrhagic Escherichia coli-contaminated food products are among the leading causes of bacterial enteric infections in the United States and worldwide. Currently, other than thermal inactivation, there are no effective methods to control pathogenic bacteria in food. We investigated colicins, nonantibiotic antimicrobial proteins produced by certain E. coli strains and active against other strains of the species, as potential pathogen control agents. We demonstrate that most colicins can be expressed at high yields in plants and are fully functional. We show that mixtures of colicins applied at low concentrations are highly and broadly active against all major pathogenic E. coli strains of concern for foodborne illness. We propose plant-produced colicins as an inexpensive food treatment for the broad control of pathogenic E. coli strains. Enterohemorrhagic Escherichia coli (EHEC) is one of the leading causes of bacterial enteric infections worldwide, causing ∼100,000 illnesses, 3,000 hospitalizations, and 90 deaths annually in the United States alone. These illnesses have been linked to consumption of contaminated animal products and vegetables. Currently, other than thermal inactivation, there are no effective methods to eliminate pathogenic bacteria in food. Colicins are nonantibiotic antimicrobial proteins, produced by E. coli strains that kill or inhibit the growth of other E. coli strains. Several colicins are highly effective against key EHEC strains. Here we demonstrate very high levels of colicin expression (up to 3 g/kg of fresh biomass) in tobacco and edible plants (spinach and leafy beets) at costs that will allow commercialization. Among the colicins examined, plant-expressed colicin M had the broadest antimicrobial activity against EHEC and complemented the potency of other colicins. A mixture of colicin M and colicin E7 showed very high activity against all major EHEC strains, as defined by the US Department of Agriculture/Food and Drug Administration. Treatments with low (less than 10 mg colicins per L) concentrations reduced the pathogenic bacterial load in broth culture by 2 to over 6 logs depending on the strain. In experiments using meats spiked with E. coli O157:H7, colicins efficiently reduced the population of the pathogen by at least 2 logs. Plant-produced colicins could be effectively used for the broad control of pathogenic E. coli in both plant- and animal-based food products and, in the United States, colicins could be approved using the generally recognized as safe (GRAS) regulatory approval pathway.

[1]  N. Rigby,et al.  Gastro‐duodenal digestion products of the major peanut allergen Ara h 1 retain an allergenic potential , 2006, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[2]  Ernst Weber,et al.  A Modular Cloning System for Standardized Assembly of Multigene Constructs , 2011, PloS one.

[3]  Carola Engler,et al.  Rapid high-yield expression of full-size IgG antibodies in plants coinfected with noncompeting viral vectors , 2006, Proceedings of the National Academy of Sciences.

[4]  S. Streatfield,et al.  Safety and Immunogenicity of a Plant-Produced Recombinant Hemagglutinin-Based Influenza Vaccine (HAI-05) Derived from A/Indonesia/05/2005 (H5N1) Influenza Virus: A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study in Healthy Adults , 2012, Viruses.

[5]  S. Lonergan,et al.  Colicin concentrations inhibit growth of Escherichia coli O157:H7 in vitro. , 2004, Journal of food protection.

[6]  Alan R Mackie,et al.  Comparative resistance of food proteins to adult and infant in vitro digestion models. , 2010, Molecular nutrition & food research.

[7]  J. Wells,et al.  Non-O157 Shiga toxin-producing Escherichia coli infections in the United States, 1983-2002. , 2005, The Journal of infectious diseases.

[8]  R. Roberts,et al.  Evaluation of colicins for inhibitory activity against diarrheagenic Escherichia coli strains, including serotype O157:H7 , 1996, Applied and environmental microbiology.

[9]  Anna K. Johnson,et al.  Dietary Inclusion of Colicin E1 Is Effective in Preventing Postweaning Diarrhea Caused by F18-Positive Escherichia coli in Pigs , 2007, Antimicrobial Agents and Chemotherapy.

[10]  Martyn D Kirk,et al.  Global incidence of human Shiga toxin-producing Escherichia coli infections and deaths: a systematic review and knowledge synthesis. , 2014, Foodborne pathogens and disease.

[11]  S. Lonergan,et al.  Application of colicin E1 as a prefabrication intervention strategy. , 2008, Journal of food protection.

[12]  S. Hahn,et al.  A novel and fully scalable Agrobacterium spray-based process for manufacturing cellulases and other cost-sensitive proteins in plants. , 2015, Plant biotechnology journal.

[13]  Klaus Stark,et al.  Epidemic profile of Shiga-toxin-producing Escherichia coli O104:H4 outbreak in Germany. , 2011, The New England journal of medicine.

[14]  J. Konisky Characterization of colicin Ia and colicin Ib. Chemical studies of protein structure. , 1972, The Journal of biological chemistry.

[15]  R. Isaacson,et al.  Characterization of Colicin Ia and Colicin Ib: Antigenic Homology , 1972, Journal of bacteriology.

[16]  E. Mills,et al.  Stability of the major allergen Brazil nut 2S albumin (Ber e 1) to physiologically relevant in vitro gastrointestinal digestion , 2005, The FEBS journal.

[17]  Tiffany Tu,et al.  Manufacturing Economics of Plant-Made Biologics: Case Studies in Therapeutic and Industrial Enzymes , 2014, BioMed research international.

[18]  A. Ražanskienė,et al.  High-yield production of a functional bacteriophage lysin with antipneumococcal activity using a plant virus-based expression system. , 2015, Journal of biotechnology.

[19]  J. Fry,et al.  A simple and general method for transferring genes into plants. , 1985, Science.

[20]  S. Marillonnet,et al.  Rapid, high-yield production in plants of individualized idiotype vaccines for non-Hodgkin's lymphoma. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  C. Saegerman,et al.  Antimicrobial Resistance in the Food Chain: A Review , 2013, International journal of environmental research and public health.

[22]  V. Braun,et al.  Primary structure of colicin M, an inhibitor of murein biosynthesis , 1987, Journal of bacteriology.

[23]  S. Gaier,et al.  In vitro digestibility of beta-casein and beta-lactoglobulin under simulated human gastric and duodenal conditions: a multi-laboratory evaluation. , 2009, Regulatory toxicology and pharmacology : RTP.

[24]  U. Bauer,et al.  [Centers for Disease Control and Prevention (CDC)]. , 2000, Annales de dermatologie et de venereologie.

[25]  S. Marillonnet,et al.  Systemic Agrobacterium tumefaciens–mediated transfection of viral replicons for efficient transient expression in plants , 2005, Nature Biotechnology.

[26]  Brian J. Ward,et al.  Preclinical and Clinical Development of Plant-Made Virus-Like Particle Vaccine against Avian H5N1 Influenza , 2010, PloS one.

[27]  R. Bock,et al.  Plastid production of protein antibiotics against pneumonia via a new strategy for high-level expression of antimicrobial proteins , 2009, Proceedings of the National Academy of Sciences.

[28]  V. Braun,et al.  Nucleotide sequence of the colicin B activity gene cba: consensus pentapeptide among TonB-dependent colicins and receptors , 1987, Journal of bacteriology.

[29]  G. Bertani,et al.  STUDIES ON LYSOGENESIS I , 1951, Journal of bacteriology.

[30]  S. Werner,et al.  High-level recombinant protein expression in transgenic plants by using a double-inducible viral vector , 2011, Proceedings of the National Academy of Sciences.